Transcatheter valve replacement helps patients with limited heart care options For patients facing heart valve disease who are not candidates for traditional open-heart surgery, transcatheter valve replacement offers a life-saving alternative. This minimally invasive procedure delivers a new valve through a catheter, typically inserted via the femoral artery, avoiding the need for large incisions and cardiopulmonary bypass. It is most commonly used to treat aortic stenosis but is increasingly applied to mitral and other valve conditions. Transcatheter aortic valve replacement (TAVR), also known as transcatheter aortic valve implantation (TAVI), has grow a standard treatment for severe aortic stenosis, particularly in patients deemed high or extreme risk for surgical valve replacement. Clinical trials have demonstrated that TAVR provides comparable or superior outcomes to surgical aortic valve replacement in terms of mortality, stroke risk, and quality of life, even in lower-risk populations. The procedure involves collapsing a bioprosthetic valve mounted on a stent-like frame and delivering it to the diseased valve site, where it is expanded to push aside the faulty native valve leaflets and restore proper blood flow. Beyond aortic valve disease, transcatheter therapies are evolving to address mitral valve regurgitation and stenosis. Devices such as the MitraClip enable percutaneous repair of the mitral valve by grasping the leaflets to reduce backward blood flow. Early feasibility studies, including those evaluating atrial fixation transcatheter mitral valve replacement systems, suggest sustained clinical benefits one year post-procedure in patients with leaky mitral valves who lack other treatment options. These innovations expand access to care for individuals previously considered too frail or high-risk for conventional surgery. Heart valve replacement options broadly fall into two categories: mechanical valves and biological (tissue) valves. Mechanical valves, made from durable materials like pyrolytic carbon, offer long-term durability but require lifelong anticoagulation therapy to prevent blood clots. Biological valves, derived from porcine or bovine tissue or human donors (homografts), typically last 10 to 20 years and do not usually necessitate long-term anticoagulation, though they may degrade faster, especially in younger patients. The Ross procedure, which involves replacing the diseased aortic valve with the patient’s own pulmonary valve and implanting a homograft in the pulmonary position, is another surgical option, primarily considered in younger adults to avoid anticoagulation. Minimally invasive techniques, including mini-sternotomy and right thoracotomy approaches, continue to reduce surgical trauma, shorten hospital stays, and speed recovery compared to full median sternotomy. These methods are increasingly combined with transcatheter technologies to create hybrid strategies tailored to individual anatomy and risk profiles. The choice of valve replacement method depends on multiple factors, including the specific valve affected, the nature and severity of dysfunction (stenosis vs. Regurgitation), patient age, comorbidities, lifestyle, and personal values. While age alone does not determine eligibility, frailty, liver disease, renal dysfunction, and prior chest radiation can influence procedural suitability. Shared decision-making between patients and their heart care teams is essential, incorporating evidence-based guidelines and individual preferences. As transcatheter platforms advance, expanding indications and improving durability, more patients with limited heart care options are gaining access to effective treatments. Ongoing research focuses on enhancing valve longevity, reducing paravalvular leak, and developing fully recapturable and repositionable systems. For individuals diagnosed with heart valve disease, consulting a multidisciplinary structural heart program ensures evaluation for the full spectrum of available therapies, from traditional surgery to cutting-edge catheter-based interventions.
50